Table 3 Incidence of hematologic adverse events before/after palbociclib dose reduction from 100 to 75 mg
Adverse event | Before dose reduction (N = 105) | After dose reduction | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cycle 1 (N = 105) | Cycle 2 (N = 98) | Cycle 3 (N = 94) | Cycle 4 (N = 88) | Cycle 5 (N = 80) | Cycle 6 (N = 73) | ||||||||||||||||
Grade, n (%) | Grade, n (%) | Grade, n (%) | Grade, n (%) | Grade, n (%) | Grade, n (%) | Grade, n (%) | |||||||||||||||
All | 3 | 4 | All | 3 | 4 | All | 3 | 4 | All | 3 | 4 | All | 3 | 4 | All | 3 | 4 | All | 3 | 4 | |
Leukopenia* | 36 (34.3) | 23 (21.9) | 0 | 29 (27.6) | 12 (11.4) | 0 | 26 (26.5) | 8 (8.2) | 0 | 22 (23.4) | 6 (6.4) | 0 | 21 (23.9) | 6 (6.8) | 0 | 16 (20.0) | 5 (6.3) | 0 | 17 (23.3) | 6 (8.2) | 0 |
Thrombocytopenia† | 15 (14.3) | 3 (2.9) | 0 | 12 (11.4) | 0 | 0 | 11 (11.2) | 0 | 0 | 6 (6.4) | 0 | 0 | 6 (6.8) | 0 | 0 | 6 (7.5) | 0 | 0 | 6 (8.2) | 0 | 0 |
Anemia‡ | 11 (10.5) | 4 (3.8) | 0 | 13 (12.4) | 3 (2.9) | 0 | 11 (11.2) | 2 (2.0) | 0 | 11 (11.7) | 1 (1.1) | 0 | 9 (10.2) | 0 | 0 | 7 (8.8) | 0 | 0 | 5 (6.8) | 1 (1.4) | 0 |
Febrile neutropenia | 1 (1.0) | 1 (1.0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1.3) | 1 (1.3) | 0 | 0 | 0 | 0 |